Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

医学 彭布罗利珠单抗 蒽环类 肉瘤 内科学 阿霉素 肿瘤科 临床终点 软组织肉瘤 平滑肌肉瘤 横纹肌肉瘤 外科 临床试验 化疗 癌症 乳腺癌 病理 免疫疗法
作者
Seth M. Pollack,Mary Weber Redman,Kelsey K. Baker,Michael J. Wagner,Brett Schroeder,Elizabeth T. Loggers,Kathryn Trieselmann,Vanessa C. Copeland,Shihong Zhang,Graeme Black,Sabrina McDonnell,Jeffrey Gregory,Rylee Johnson,Roxanne Moore,Robin L. Jones,Lee D. Cranmer
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (11): 1778-1778 被引量:160
标识
DOI:10.1001/jamaoncol.2020.3689
摘要

IMPORTANCE: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating improved outcomes. OBJECTIVE: To evaluate the safety and efficacy of doxorubicin in combination with pembrolizumab in patients with advanced, anthracycline-naive sarcomas. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial used a 2-stage phase 2 design and was performed at a single, academic sarcoma specialty center. Patients were adults with good performance status and end-organ function. Patients with all sarcoma subtypes were allowed to enroll with the exception of osteosarcoma, Ewing sarcoma, and alveolar and embryonal rhabdomyosarcoma. INTERVENTIONS: Two dose levels of doxorubicin (45 and 75 mg/m2) were tested for safety in combination with pembrolizumab. MAIN OUTCOMES AND MEASURES: Objective response rate (ORR) was the primary end point. Overall survival (OS) and progression-free survival (PFS) were secondary end points. Correlative studies included immunohistochemistry, gene expression, and serum cytokines. RESULTS: A total of 37 patients (22 men; 15 women) were treated in the combined phase 1/2 trial. The median (range) patient age was 58.4 (25-80) years. The most common histologic subtype was leiomyosarcoma (11 patients). Doxorubicin plus pembrolizumab was well tolerated without significant unexpected toxic effects. The ORR was 13% for phase 2 patients and 19% overall. Median PFS was 8.1 (95% CI, 7.6-10.8) months. Median OS was 27.6 (95% CI, 18.7-not reached) months at the time of this analysis. Two of 3 patients with undifferentiated pleomorphic sarcoma and 2 of 4 patients with dedifferentiated liposarcoma had durable partial responses. Tumor-infiltrating lymphocytes were present in 21% of evaluable tumors and associated with inferior PFS (log-rank P = .03). No dose-limiting toxic effects were observed. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, doxorubicin plus pembrolizumab was well tolerated. Although the primary end point for ORR was not reached, the PFS and OS observed compared favorably with prior published studies. Further studies are warranted, especially those focusing on undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02888665.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吃猫的鱼发布了新的文献求助10
1秒前
共享精神的应助被流星采纳,获得10
1秒前
1秒前
2秒前
冷酷的小鸭子完成签到 ,获得积分10
2秒前
3秒前
mei完成签到,获得积分10
4秒前
hui发布了新的文献求助30
5秒前
Uzma完成签到,获得积分10
6秒前
酷波er的应助被包容映安采纳,获得10
7秒前
科研通AI6.3的应助被奥特赛文采纳,获得10
7秒前
sx完成签到,获得积分10
7秒前
极限001的应助被奥特赛文采纳,获得30
7秒前
7秒前
共享精神的应助被lykkk采纳,获得10
7秒前
健忘白猫发布了新的文献求助20
8秒前
BAEKHYUNLUCKY发布了新的文献求助10
8秒前
粗心的鹏笑完成签到,获得积分10
9秒前
10秒前
sdl发布了新的文献求助10
10秒前
minilysum发布了新的文献求助10
10秒前
11秒前
lilili完成签到,获得积分10
11秒前
希望天下0贩的0的应助被haha采纳,获得10
12秒前
星辰大海的应助被周什么园采纳,获得10
12秒前
zcy发布了新的文献求助10
12秒前
EVE_AElle_Lee完成签到,获得积分10
12秒前
科研通AI65的应助被YC采纳,获得30
12秒前
Hase发布了新的文献求助50
13秒前
搜集达人的应助被壮壮采纳,获得10
13秒前
明理的凛完成签到,获得积分10
14秒前
研友_8KX15L发布了新的文献求助30
14秒前
小鱼小鱼快快游完成签到,获得积分10
15秒前
15秒前
Owen的应助被奋斗小真采纳,获得10
16秒前
关你peace完成签到,获得积分20
16秒前
满意元枫完成签到,获得积分10
16秒前
16秒前
ZeKaWa给咯噔的求助进行了留言
16秒前
贝果完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175305
求助须知:如何正确求助?哪些是违规求助? 9567097
关于积分的说明 21790117
捐赠科研通 7769782
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241